Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q2- Text added to 2023 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
abdomen, atezolizumab, attacked, begun, Biden, concentration, delayed, detailing, distribution, enacted, exploratory, federal, gemcitabine, government, guaranty, hedging, institution, insurance, insured, Israel, Lancet, mitigate, paid, President, Pritesh, published, resign, resolution, Roche, rolling, Shah, short, stop, subgroup, subsequently, suggested, tier, torso, war
Removed:
concurrent, criteria, gain, optimal, pilot, pivotal, radiation, stage, successfully
Valuein 2023 Q2 filing- Value in 2023 Q3 filing
Original filings
Filing view